Morgan Stanley Aldeyra Therapeutics, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 775,036 shares of ALDX stock, worth $4.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

775,036

Previous 555,059 39.63%

Holding current value

$4.26 Million

Previous $3.19 Million 6.99%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$1.42 - $5.48 $312,367 - $1.21 Million	219,977 Added 39.63%	775,036 $2.97 Million
Q1 2025 May 15, 2025	SELL	$4.7 - $6.98 $115,883 - $172,098	-24,656 Reduced 4.25%	555,059 $3.19 Million
Q4 2024 Feb 14, 2025	BUY	$4.21 - $5.9 $248,680 - $348,507	59,069 Added 11.35%	579,715 $2.89 Million
Q3 2024 May 14, 2025	BUY	$3.19 - $6.32 $667,481 - $1.32 Million	209,242 Added 67.19%	520,646 $2.81 Million
Q3 2024 Nov 14, 2024	BUY	$3.19 - $6.32 $667,481 - $1.32 Million	209,242 Added 67.19%	520,646 $2.81 Million
Q2 2024 May 14, 2025	SELL	$3.25 - $4.72 $872,010 - $1.27 Million	-268,311 Reduced 46.28%	311,404 $1.03 Million
Q2 2024 Oct 17, 2024	SELL	$3.25 - $4.72 $123,961 - $180,030	-38,142 Reduced 10.91%	311,404 $1.03 Million
Q2 2024 Aug 14, 2024	SELL	$3.25 - $4.72 $123,961 - $180,030	-38,142 Reduced 10.91%	311,404 $1.03 Million
Q1 2024 Oct 17, 2024	BUY	$2.77 - $4.22 $105,653 - $160,959	38,142 Added 12.25%	349,546 $1.14 Million
Q1 2024 Aug 16, 2024	SELL	$2.77 - $4.22 $195,345 - $297,602	-70,522 Reduced 16.79%	349,546 $1.14 Million
Q1 2024 May 15, 2024	SELL	$2.77 - $4.22 $195,345 - $297,602	-70,522 Reduced 16.79%	349,546 $1.14 Million
Q4 2023 Aug 16, 2024	BUY	$1.47 - $6.06 $159,736 - $658,503	108,664 Added 34.89%	420,068 $1.47 Million
Q4 2023 Feb 13, 2024	BUY	$1.47 - $6.06 $251,300 - $1.04 Million	170,953 Added 68.62%	420,068 $1.47 Million
Q3 2023 Nov 15, 2023	SELL	$6.11 - $8.16 $439,388 - $586,810	-71,913 Reduced 22.4%	249,115 $1.66 Million
Q2 2023 Aug 14, 2023	SELL	$7.11 - $11.89 $6.11 Million - $10.2 Million	-858,935 Reduced 72.79%	321,028 $2.69 Million
Q1 2023 May 15, 2023	BUY	$5.77 - $9.93 $4.99 Million - $8.59 Million	864,713 Added 274.29%	1,179,963 $11.7 Million
Q4 2022 Feb 14, 2023	BUY	$5.08 - $7.09 $64,043 - $89,383	12,607 Added 4.17%	315,250 $2.19 Million
Q3 2022 Nov 14, 2022	SELL	$3.8 - $7.74 $236,804 - $482,333	-62,317 Reduced 17.08%	302,643 $1.62 Million
Q2 2022 Oct 27, 2022	BUY	$2.43 - $4.85 $28,698 - $57,278	11,810 Added 3.34%	364,960 $1.46 Million
Q2 2022 Aug 15, 2022	BUY	$2.43 - $4.85 $28,698 - $57,278	11,810 Added 3.34%	364,960 $1.46 Million
Q1 2022 Oct 27, 2022	SELL	$3.25 - $5.17 $38,382 - $61,057	-11,810 Reduced 3.24%	353,150 $1.57 Million
Q1 2022 May 13, 2022	BUY	$3.25 - $5.17 $584,824 - $930,320	179,946 Added 103.89%	353,150 $1.57 Million
Q4 2021 Feb 14, 2022	BUY	$3.5 - $9.63 $413,294 - $1.14 Million	118,084 Added 214.23%	173,204 $693,000
Q3 2021 Nov 15, 2021	BUY	$7.94 - $11.31 $437,652 - $623,407	55,120 New	55,120 $483,000

Others Institutions Holding ALDX

# of Institutions

132

Shares Held

34.9M

Call Options Held

244K

Put Options Held

51.6K

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $321M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account